Bioidentical Hormone Replacement Therapy: What It Is and Is It Safer?

"Bioidentical" gets used in clinic marketing as if it were a safety rating, and the first thing to know is that it is not one. "Bioidentical" is not the same as "compounded": FDA has approved many hormone products — estradiol, progesterone and testosterone among them — that are reviewed for safety and efficacy, while compounded "BHRT" blends are not FDA-reviewed.

That is the split the research actually sorts products by: whether a hormone preparation is an FDA-approved drug with a label, or a custom-compounded blend mixed for an individual patient.

A product can therefore be bioidentical without being compounded, because FDA-approved estradiol and progesterone products have been through that review.

The compounded preparations are the category the National Academies review examined, and the one whose claims this page checks.

Whether compounded hormones really are more natural, safer or better than FDA-approved hormones is a testable claim — and the National Academies review commissioned by FDA found no rigorous evidence for it.

The rest of this page is that evidence.

FDA has approved dozens of hormone therapy products for men and women, including estrogen, progesterone, testosterone and related compounds.

These products are reviewed for safety and efficacy, and they carry labels with named indications and warnings.

Compounded "BHRT" works differently.

A compounding pharmacy mixes a custom preparation for an individual patient, and those preparations are not FDA-reviewed.

The National Academies notes that compounded hormone preparations are not required to demonstrate safety or effectiveness before they are dispensed to patients.

The market is large.

NASEM estimated 26 to 33 million compounded hormone prescriptions a year, costing upwards of $2 billion — figures for the compounded hormone market overall, not for any one clinic or product.

The difference reaches the labeling process itself.

On November 10, 2025, FDA announced it was initiating removal of the boxed-warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, while keeping the boxed warning on endometrial cancer for systemic estrogen-alone products.

An FDA action on product labels is exactly the oversight compounded preparations sit outside.

This is the question the marketing answers with "yes," and it is the question the evidence does not.

The central piece of evidence is a 2020 National Academies (NASEM) report commissioned by FDA.

It concluded there is insufficient evidence to support the clinical utility of compounded bioidentical hormone therapy (cBHT) for menopause or male hypogonadism symptoms, and recommended restricting its use.

On safety specifically: compounded hormone preparations reach patients without any requirement to demonstrate safety or effectiveness first.

An FDA-approved hormone product, by contrast, has been reviewed for safety and efficacy and carries a label stating its indications and warnings.

The review also took up the comparison the marketing claims directly.

NASEM found no rigorous evidence that compounded bioidentical hormones are safer, more natural or better than FDA-approved hormones, and the clinical guidance it surveyed cautions against using cBHT preparations in place of FDA-approved options.

FDA-approved hormones carry their own labeled risks.

In the same November 2025 labeling action described above, FDA announced it was initiating removal of some boxed-warning language while keeping the boxed warning on endometrial cancer for systemic estrogen-alone products — approved products still carry labeled warnings.

So the honest answer to "is it safer?" is: for the compounded products sold as BHRT, the review commissioned by FDA found no rigorous evidence supporting that claim.

Which product fits your situation is a question for a licensed prescriber who can see your history and the specific product's label.

Programs differ clinic by clinic, and nothing in our research documents a standard package — so treat the pieces below as questions to ask, not a fixed menu.

One form to understand in advance is pellets: small hormone implants placed under the skin.

The National Academies recommended that FDA's Pharmacy Compounding Advisory Committee consider all compounded hormone pellets as candidates for its "Difficult to Compound" list.

The approval picture for pellets is thin.

The only FDA-approved hormone pellet our research found is Testopel — testosterone pellets, 75 mg each, for subcutaneous implantation — indicated for testosterone replacement in males with primary or hypogonadotropic hypogonadism.

We did not find an FDA-approved estradiol pellet; on that basis, the estradiol and testosterone pellets for women used at some clinics appear to be compounded preparations rather than FDA-approved products.

Labs are the other piece to question.

In the sources this research read — FDA drug labels and the abstract (not the full text) of the Menopause Society's 2022 position statement among them — we did not find a requirement for routine hormone blood levels to diagnose menopause or to set menopausal HRT doses.

If a program presents a hormone or saliva panel as mandatory, ask which guideline requires it and what the results would change about your treatment.

Price is the last piece, and we could not confirm a national figure for bioidentical or any other hormone program.

Ask each clinic what the all-in cost covers — consultation, labs, the preparation itself, insertion visits and follow-up.

Prescribing and supervision, the legal spine of any program, are covered in detail in our hormone replacement therapy guide.

The product question comes first: ask which exact preparation you would receive, and whether it is an FDA-approved drug with a label or a compounded blend mixed by a pharmacy.

That one answer sorts everything else — the review the product has been through, the label you can read and the evidence behind it.

A few answers should give you pause: claims of assured results, or a pitch that compounded hormones are safer, more natural or better than FDA-approved options — the National Academies found no rigorous evidence for that.

For the general vetting steps — the medical director, the licenses you can verify, who actually treats you — our how to choose a med spa checklist applies to hormone clinics as much as to injection practices.

Nothing on this page is a recommendation for or against bioidentical hormone therapy.

The National Academies findings above, and any product's own label, are the material to take into a conversation with a licensed clinician who can see your full history.